文献速递肝病消化道肿瘤与早癌

血清生物标志物联合超声用于高危患者早期肝癌检测的随机对照试验

Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial.
PubMed 文献 · Gastroenterology · 2026-01-20

该随机对照试验纳入肝硬化或高危HBV感染成人1208例,比较每半年单独超声(A组)与超声联合血清标志物(B组)对早期HCC的检出效果。

要点

  • 超声联合AFP、AFP-L3、DCP未提高早期HCC检出率。
  • 两组早期HCC检出风险比0.81(95%CI 0.47-1.40),无统计学差异。
  • B组中单独AFP-L3升高与联合三种标志物效果相当。

核心结论

  • 在每半年超声基础上联合AFP、AFP-L3和DCP并未改善早期HCC检出。

研究设计与样本

  • 随机对照试验,纳入肝硬化或高危HBV感染成人1208例,1:1随机分为单独超声组(603例)和超声联合血清标志物组(605例)。

主要发现

  • A组发生35例HCC(5.8%),其中早期30例、晚期5例;B组发生27例HCC(4.5%),其中早期22例、晚期5例。
  • 早期HCC累积概率52周为1.3%,260周为5.9%。
  • B组中单独AFP-L3升高与联合三种标志物效果相当。

关键数值与推荐

  • 超声阳性或生物标志物升高(AFP>100 ng/mL、AFP-L3>10%、DCP>2 ng/mL)触发进一步影像学确诊HCC。

临床怎么用

  • 对于肝硬化或高危HBV感染患者,每半年超声联合AFP、AFP-L3和DCP并未优于单独超声,不推荐常规联合三种标志物用于早期HCC监测。

局限性

  • 该试验统计效能不足,无法提供证据表明在超声联合AFP之外加用其他标志物可改善HCC监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) surveillance is key to early diagnosis and timely curative treatment. Current strategies are suboptimal with many patients presenting with advanced HCC. This randomized controlled trial compared the combined use of serum biomarker (BM) measurements and abdominal ultrasound (US) with US alone for the diagnosis of early-stage HCC. METHODS: Adults with cirrhosis or high-risk hepatitis B virus (HBV) infection were randomized (1:1) to biannual surveillance with US alone (group A) or US and BMs (group B) in blocks of 2 or 4. Positive US results or elevated BMs (α-fetoprotein [AFP] >100 ng/mL, lectin-reactive fraction of AFP [AFP-L3] >10%, des-gamma-carboxy prothrombin [DCP] >2 ng/mL) triggered further imaging for HCC confirmation. Primary end point was proportion of early-stage HCCs. RESULTS: There were 1208 patients randomized (n = 603 group A, n = 605 group B). Mean ± SD age was 58.4 ± 9.8 years, 71.8% were male, 55.1% were Asian, 64.0% had HBV, and 64.3% had cirrhosis. During follow-up, 35 HCCs (5.8%) developed in group A (n = 30 early-stage, n = 5 late-stage) and 27 (4.5%) developed in group B (n = 22 early-stage, n = 5 late-stage). Early-stage HCC incidence was 1.2 per 100 person-years with cumulative probabilities of 1.3% at 52 weeks and 5.9% at 260 weeks. Early-stage HCC detection rate did not differ by study arm (hazard ratio, 0.81; 95% CI, 0.47-1.40; P = .45). In group B, elevated AFP-L3 was equally effective compared with using all 3 BMs. CONCLUSIONS: Addition of AFP, AFP-L3, and DCP to biannual US did not improve early-stage HCC detection. The trial was not adequately powered to provide evidence that the use of BMs aside from US plus AFP improves HCC surveillance. Establishing and validating alternative approaches to incorporation of BMs may improve surveillance methods for early-stage HCC detection. CLINICALTRIALS: gov, Number: NCT02272504.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Hirode G, Zangneh HF, Cerocchi O, et al. Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial. Gastroenterology. 2026. PMID: 41556856. doi:10.1053/j.gastro.2025.09.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。